NEW YORK, Jan. 4 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), an international manufacturer and marketer of pharmaceutical
products, will release its Fiscal 2008 Third Quarter financial results
before the U.S. stock market opens on Tuesday, January 15, 2008. Later that
day, at 10:00 AM EST, Forest will host a conference call where Dr. Lawrence
Olanoff, President and Chief Operating Officer and Frank Perier, Senior
Vice President and Chief Financial Officer, will discuss the financial
results and relevant company and industry topics. The conference call will
be webcast live beginning at 10:00 AM EST on the Company's website
http://www.frx.com and also on the website http://www.streetevents.com. Please log on to
either website at least fifteen minutes prior to the conference call as it
may be necessary to download software to access the call. A replay of the
conference call will be available until January 31, 2008 at both websites
and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291
(international investors), ID 30069630.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical company
dedicated to identifying, developing and delivering products that make a
positive difference in peoples' lives. Forest Laboratories' growing product
line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for
adults for the initial and maintenance treatment of major depressive
disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment
of moderate to severe Alzheimer's disease; and Campral(R)* (acamprosate
calcium), indicated in combination with psychosocial support for the
maintenance of abstinence from alcohol in patients with alcohol dependence
who are abstinent at treatment initiation. In addition to our growing
product line, Forest also co-promotes the Daiichi Sankyo, Inc. products
Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker,
Benicar HCT(R)* (olmesartan medoxomil-hydrochlorothiazide), an angiotensin
receptor blocker and diuretic combination product, and AZOR(TM)*
(amlodipine and olmesartan medoxomil) a calcium channel blocker and
angiotensin receptor blocker combination product, all indicated for the
treatment of hypertension.
*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT
are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a
registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
each of Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President - Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
